Roche Holdings, Inc. /
Telavant
Roche Holdings, Inc. completes acquisition of Telavant
What happened
Roche Holdings, Inc. completed its acquisition of Telavant on Dec. 14, 2023. The transaction included approximately $7.1 billion in cash, with an additional $150 million payable upon the initiation of a Phase 3 trial in ulcerative colitis.
Telavant holds the rights in the US and Japan to RVT-3101, a therapy in development for inflammatory bowel disease.
The source
Everything on this page comes from the source below.
Roche Holdings, Inc. completes acquisition of Telavant
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly